O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+2.19%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.03B
AUM Growth
+$5.03B
(-7.7%)
Cap. Flow
-$321M
Cap. Flow
% of AUM
-6.38%
Top 10 Holdings %
Top 10 Hldgs %
44.26%
Holding
122
New
8
Increased
22
Reduced
23
Closed
12
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$60.8M |
| 2 |
Integer Holdings
ITGR
|
$40.4M |
| 3 |
argenx
ARGX
|
$24.7M |
| 4 |
Exact Sciences
EXAS
|
$22.5M |
| 5 |
Amgen
AMGN
|
$22.3M |
Top Sells
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$106M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$103M |
| 3 |
Janux Therapeutics
JANX
|
$54.3M |
| 4 |
Esperion Therapeutics
ESPR
|
$36.7M |
| 5 |
Praxis Precision Medicines
PRAX
|
$28.1M |
Sector Composition
| 1 | Healthcare | 99.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Vera Therapeutics
VERA
$1.47B
| $24.5M | 0.48% |
675,872
| – | – |
|
52
scPharmaceuticals
SCPH
$296M
| $24.2M | 0.48% |
5,559,528
| – | – |
|
53
Regeneron Pharmaceuticals
REGN
$59.8B
| $24M | 0.47% |
22,800
| – | – |
|
54
Mineralys Therapeutics
MLYS
$1.94B
| $23.7M | 0.47% |
2,021,424
| – | – |
|
55
Immatics
IMTX
$662M
| $23.3M | 0.46% |
2,006,381
+236,673
| +13% | +$2.75M |
|
56
Heron Therapeutics
HRTX
$204M
| $22.8M | 0.45% |
6,512,866
-3,598,684
| -36% | -$12.6M |
|
57
Compass Therapeutics
CMPX
$466M
| $22.4M | 0.44% |
22,362,850
| – | – |
|
|
MORF
58
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $20.9M | 0.41% |
612,500
+54,000
| +10% | +$1.84M |
|
59
Vir Biotechnology
VIR
$765M
| $20.6M | 0.41% |
2,320,102
+1,680,102
| +263% | +$15M |
|
60
Cullinan Oncology
CGEM
$456M
| $20M | 0.4% |
1,147,655
+630,049
| +122% | +$11M |
|
|
SLRN
61
DELISTED
ACELYRIN
SLRN
| $17.6M | 0.35% |
4,001,711
| – | – |
|
62
Apogee Therapeutics
APGE
$2.27B
| $14.9M | 0.29% |
379,130
-339,771
| -47% | -$13.4M |
|
63
Neumora Therapeutics
NMRA
$283M
| $14.7M | 0.29% |
1,500,000
| – | – |
|
64
Adicet Bio
ACET
$60.8M
| $13.9M | 0.27% |
11,447,140
| – | – |
|
65
ADC Therapeutics
ADCT
$370M
| $13.6M | 0.27% |
+4,316,824
| New | +$13.6M |
|
66
Corvus Pharmaceuticals
CRVS
$419M
| $12.6M | 0.25% |
6,943,654
| – | – |
|
67
AbCellera Biologics
ABCL
$1.19B
| $12.4M | 0.24% |
4,180,768
| – | – |
|
68
Tyra Biosciences
TYRA
$657M
| $12.3M | 0.24% |
768,638
| – | – |
|
69
TELA Bio
TELA
$65.4M
| $11.6M | 0.23% |
2,457,542
-378,000
| -13% | -$1.78M |
|
70
ALX Oncology
ALXO
$54.6M
| $11.4M | 0.23% |
1,894,462
-823,508
| -30% | -$4.97M |
|
71
Repare Therapeutics
RPTX
$73.9M
| $11M | 0.22% |
3,322,488
| – | – |
|
72
PMV Pharmaceuticals
PMVP
$82.1M
| $10.5M | 0.21% |
6,475,291
| – | – |
|
73
Lexicon Pharmaceuticals
LXRX
$392M
| $9.82M | 0.19% |
5,846,100
+2,304,100
| +65% | +$3.87M |
|
74
Lyell Immunopharma
LYEL
$220M
| $9.29M | 0.18% |
6,405,098
+6,205,598
| +3,111% | +$9M |
|
75
Merus
MRUS
$5.04B
| $9.24M | 0.18% |
+156,100
| New | +$9.24M |
|